Note
Medicine is continually subject to a process of development and change so that all information, particularly all information on diagnostic and therapeutic treatments, can only reproduce the state of knowledge at the time of printing of this guideline on care. The greatest possible care was taken when compiling these recommendations on therapy and the choice and dosage of medications.
Users are requested to consult the package leaflets and check the summary of product characteristics provided by manufacturers and, when in doubt, to consult a specialist. In the interests of all concerned, please contact the OL editorial office if you find discrepancies or controversial issues.
Users are responsible for all diagnostic and therapeutic applications, medications and dosages. 
Target audience
The guideline was compiled with the aim of providing high-risk groups with advice on diagnostics, surgical and systemic therapy in early and advanced stages of disease together with the treatment of rare histological subtypes. A lot of emphasis has been placed on follow-up care, rehabilitation, palliative therapy and psycho-oncological counselling. The recommendations are for physicians working both in hospitals and outpatient clinics, nursing staff and other medical partners involved in treating patients with malignant ovarian tumours. As it also covers the topics 'Screening' and 'Follow-up', registered physicians working in their own practice are also an important target audience of this guideline. It is additionally intended to offer guidance to affected patients and persons seeking more information as well as providing a basis for the gynaecological cancer centres currently being set up in Germany. For the first time, scientific medical societies in Switzerland and Austria were also consulted, expanding the scope of this guideline.
Methodology
The methodological approach used to compile the guideline has been described in the guideline report. The guideline report is freely available online (in German), for example on the website of the German Guideline Programme in Oncology (http:// leitlinienprogramm-onkologie.de/Leitlinien.7.0.html) and the pages of the AWMF (http://www.awmf.org/).
SIGN level of evidence system
To classify the risk of bias or confounding in the identified studies, this guideline has used the level of evidence system of the Scottish Intercollegiate Guidelines Network (SIGN, Version 2009) (http://www.sign.ac.uk/pdf/sign50.pdf) as described in l " Table 1 below.
System of grading recommendations
The OL methodology uses the grades of recommendation awarded by the authors of the guideline. The level of recommendation is decided on in a formal consensus process, using a multistep nominal group technique moderated by the AWMF. The guideline includes the level of evidence (SIGN, see 2.2.1) of the studies on which they are based as well as the strength of the recommendation (grade of recommendation) for all evidence-based statements (see chapter 2.2.3) and recommendations. This guideline has three different 'strength of recommendation' ratings (see l " Table 2 below), which are also reflected in the formulation of the recommendation.
Statements
Statements are expositions or explanations of specific facts or issues which do not constitute a call for action. They are approved in a similar manner to that used for recommendations in a formal consensus process and may be based either on study results or expert opinions.
Clinical consensus (CC)
Statements/recommendations which were drawn up on the basis of a consensus of experts from the guideline group are identified by the term "clinical consensus". No symbols were used to grade the clinical consensus; the strength of the consensus is indicated by the formulations used (must, necessary/should/can) as described for the gradations in l " Table 2 .
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Level Description

1++
High quality meta-analyses, systematic reviews of randomised controlled trials (RCTs), or RCTs with a very low risk of bias 1+
Well conducted meta-analyses, systematic reviews of RCTs, or RCTs with a low risk of bias 1− Meta-analyses, systematic reviews of RCTs, or RCTs with a high risk of bias 2++
High quality systematic reviews of case-control or cohort studies, or high quality case control or cohort studies with a very low risk of confounding or bias ("chance") and a high probability that the relationship is causal 2+
Well conducted case-control or cohort studies with a low risk of of confounding or bias ("chance") and a moderate probability that the relationship is causal 2− Case-control or cohort studies with a high risk of confounding or bias ("chance") and a significant risk that the relationship is not causal 3
Non-analytic studies, e.g. case reports, case series 4
Expert opinion of interest disclosed are included in the guideline report to this guideline (http://leitlinienprogramm-onkologie.de/Leitlinien. 7.0.html). We would like to take this opportunity of thanking all contributors for their contribution to the project, which was entirely voluntary and unsalaried.
Period of validity and update process
This S3-guideline will remain valid until it is next updated; its estimated period of validity is 3 years. Regular updates are planned; if an urgent need for changes to the guideline occurs in between update times, these changes will be published separately. Comments and advice for the update process are expressly requested and should be sent to the following address: Prof. Dr. Uwe Wagner, Klinik für Gynäkologie, gynäkologische Endokrinologie und Onkologie, Baldingerstraße, D-35043 Marburg, Germany; phone: 06 421-58-66 211, fax: 0 642 158-68 969, e-mail: wagneru@med.uni-marburg.de. The information provided by the physician to the patient must include information on the disease, the results of the examination(s), the course of treatment to date, the diagnostic and therapeutic options including expected side-effects as well as the assessment of the associated prognosis and the impact on the patientʼs life plans and quality of life. Written materials and other suitable media can be used to help explain all of this to the patient and as aids in decision-making. Conveying this information and explaining it to the patient must be done based on the following principles of patient-centred communication: " The physician must show empathy and use active listening " Difficult topics must be touched upon directly and sensitively " Avoid using specialised medical vocabulary; explain specialist terminology where necessary " Use strategies to improve the patientʼs comprehension (repetition, summarising of important information, use of diagrams and graphs) " Encourage the patient to ask questions " Permit and encourage the patient to express her feelings, particularly her worries and fears " Offer further help The patientʼs wishes about being involved in the process of medical decision-making must be taken into account.
List of abbreviations
CC
No.
Recommendations/Statements GR LoE Sources
Bilateral salpingo-oophorectomy is the most effective method to reduce the risk of developing the disease and to reduce mortality in patients with hereditary ovarian cancer.
ST 2+
Guidelines: [1, 2] Primary studies: [11, 24-39] 5.2.
Patients with BRCA1/2 mutation should be offered prophylactic bilateral salpingo-oophorectomy; surgery should be done once the patient plans to have no more children, after the patient has either turned 40 years of age or 5 years prior to the youngest age at which a member of the patientʼs family developed ovarian cancer.
B 2+
Guidelines: [2] Primary studies: [11, [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] No. Recommendations/Statements GR LoE Sources Systematic recording of the patientʼs quality of life can be helpful to identify difficulties during treatment.
CC * Data on the effectiveness of consolidation or maintenance therapy to increase progression-free survival (PFS) is only available for bevacizumab (see 8.6.) No.
Statement GR LoE Sources 9.1. Platinum-sensitive ovarian cancer: Disease responds primarily to platinum-based first-line chemotherapy with recurrence occurring at the earliest 6 months after conclusion of platinum-based chemotherapy. This also includes the subgroup of partially platinum-sensitive recurrences of ovarian cancer. In this subgroup, disease also responds primarily to platinum-based first-line chemotherapy but recurrence occurs between 6 and 12 months after concluding platinum-based chemotherapy.
Platinum-resistant ovarian cancer: Disease recurs within the first 6 months after concluding initial platinum-based chemotherapy. This also includes the subgroup with platinumrefractory recurrence of ovarian cancer. In this subgroup, disease does not respond to platinum-based chemotherapy or disease progresses within 4 weeks after therapy has been concluded.
ST 1+
Guidelines: [1, 119] Primary studies: [14, [155] [156] [157] [158] [159] [160] [161] [162] [163] No. 
2+
Primary studies: [180] [181] [182] [183] No.
Recommendations GR LoE Sources The topic of sexuality should always be actively explored to identify when further support is required and to provide additional support as required.
CC
No.
Recommendations GR LoE Sources In mucinous borderline tumours, metastasis of extraovarian tumours must be excluded; an appendectomy is necessary to exclude a primary appendiceal neoplasm.
B 2+
Primary studies: [185] [186] [187] [188] [189] 11.3.
There are some indications that performing cystectomy instead of ovarectomy and carrying out a fertility-preserving procedure instead of bilateral salpingo-oophorectomy is associated with higher rates of recurrence.
ST 2+
Primary studies: [190] 11.4. If the patient wishes to have children/wishes to preserve endocrine functions, a fertilitypreserving procedure can be carried out. The patient must be informed about the increased risk of recurrence associated with this procedure.
2+
Guidelines: [2] Primary studies: [191] 11.5.
There is no persuasive evidence for the effectiveness of adjuvant therapy for the treatment of borderline tumours.
ST 1+
Guidelines: [2] Primary studies: [192] 11.6.
Patients with borderline tumours must not receive adjuvant therapy. A 1+ Guidelines: [2] Primary studies: [192] No.
Recommendations/Statements GR LoE Sources
12.1.
The diagnosis of germ cell and stromal tumours must done in a similar manner as the diagnosis of ovarian cancer.
CC
12.2.
Optimal staging must include the following procedures: " Lower median laparotomy " Inspection and palpation of the entire abdominal cavity " Peritoneal cytology " Removal of the tumour with salpingo-oophorectomy " For potentially malignant tumours (granulosa cell tumours, Sertoli-Leydig cell tumours G2/G3 or steroid cell tumours NOS): " Definitive operative staging analogous to that for ovarian cancer. " The benefit of systematic lymphonodectomy when lymph nodes are unremarkable has not been proven. " If the uterus is not removed, hysteroscopy and curettage are recommended (to exclude endometrial hyperplasias or endometrial carcinoma).
A 2+
Primary studies: [193] [194] [195] [196] The benefit of adjuvant radiotherapy, chemotherapy or endocrine therapy after complete resection has not been proven and is controversially discussed in the literature.
ST 2+
Primary studies: [197, 198] 
12.5.
Platinum-based chemotherapy should be considered for tumours which are stage IC or higher or if residual tumour is still present.
B 2+
Primary studies: [199] [200] [201] [202] No. Patients with ovarian cancer should be treated by a gynaecological oncologist (specialist) in a specialist facility which includes interdisciplinary diagnostic and therapeutic services.
CC
Quality indicator
Recommendation reference Evidence base/additional information Quality indicator 1: Operative staging of early ovarian cancer Z: Number of pts. with operative staging using: " laparotomy " peritoneal cytology " peritoneal biopsies " bilateral excision of adnexa of uterus " hysterectomy, using an extraperitoneal approach where necessary " infracolic omentectomy " bilateral pelvic and paraaortal lymphonodectomy N: All pts. with a primary diagnosis of ovarian cancer FIGO I -IIIA 7.1. Optimal staging must including the following procedures: " longitudinal laparotomy " inspection and palpation of the entire abdominal cavity " peritoneal cytology " biopsies from all abnormal sites " peritoneal biopsies from unremarkable regions " bilateral excision of adnexa of uterus " hysterectomy, using an extraperitoneal approach where necessary " infracolic omentectomy " appendectomy (for mucinous/unclear tumour types) " bilateral pelvic and paraaortal lymphonodectomy a) Quality target Operative staging to be done as often as possible b) Evidence base CC Guidelines: NICE 2 011 [118] Primary studies: [215] [216] [217] [218] [219] [220] [221] [222] [223] Quality indicator 2: Intraoperative tumour rupture Z: Number of pts. with intraoperative tumour rupture N: All pts. with a primary diagnosis of ovarian cancer FIGO IA or IB Background text to 7.5. "When an unclear ovarian carcinoma is removed laparoscopically, complete removal is important with no tumour rupture." a) Quality target No intraoperative tumour rupture b) Evidence base Leitlinien: [1, 2] Primärstudien: [139] [140] [141] [142] [143] Quality indicator 3: Macroscopically complete resection of advanced ovarian cancer Z: Number of pts. with macroscopically complete resection N: All pts. with a primary diagnosis of ovarian cancer ≥ FIGO IIB and surgical removal of the tumour 7.6. The goal of primary surgery must be to achieve macroscopically complete resection.
a) Quality target
Macroscopically complete resection to be achieved as often as possible b) Evidence base CC Guidelines: [1, 2] Primary studies: [75, 83, 95, 174, [224] [225] [226] [227] [228] [229] [230] [231] [232] [233] [234] [235] [236] Quality indicator 4: Surgery for advanced ovarian cancer Z: Number of pts. whose definitive surgery was done by a gynaecological oncologist N: All pts. with a primary diagnosis of ovarian cancer FIGO ≥ IIB after surgical therapy has been completed 7.8. The diagnosis for patients unexpectedly diagnosed with advanced ovarian cancer must be confirmed histologically and the extent of spread described. The definitive treatment must then be carried out by a gynaecological oncologist in a suitable facility. a) Quality target Surgery to be performed as often as possible by a gynaecological oncologist b) Evidence base LoE 4, A Guidelines: [2] Primary studies: [73] [74] [75] [76] [77] [78] [79] [80] [81] [82] [83] [84] [85] [86] [87] [88] [89] Note: Gynaecological oncologist = Medical specialist for gynaecology and obstetrics with a special focus on gynaecological oncology Quality indicator 5: Postoperative chemotherapy for advanced ovarian cancer Z: Number of pts. who received postoperative chemotherapy N: All pts. with a primary diagnosis of ovarian cancer ≥ FIGO IIB and receiving chemotherapy 7.10. The sequence of therapy must consist of primary surgery followed by chemotherapy. [118] , NHS TA91 [119] Primary studies: [120] [121] [122] [123] [124] [125] [126] [127] [128] [129] [130] [131] Quality indicator 9: Chemotherapy for platinum-resistant and/or refractory primary recurrence Z: Number of pts. who received non platinumbased monotherapy with pegylated liposomal doxorubicin, topotecan, gemcitabine or paclitaxel weekly N: All pts. with platinum-resistant and/or refractory primary recurrence of ovarian cancer receiving chemotherapy for primary recurrence outside clinical trials 9.4. Patients with platinum-resistant and/or refractory recurrence of ovarian cancer must receive non platinumbased monotherapy if chemotherapy is indicated:
The following cytostatic drugs can be considered: " pegylated liposomal doxorubicin " topotecan " gemcitabine " paclitaxel weekly a) Quality target Non platinum-based monotherapy (s. left) to be administered as often as possible to treat patients with platinum-resistant and/or refractory primary recurrence of ovarian cancer receiving chemotherapy for primary recurrence outside clinical trials b) Evidence base LoE 1+, A Guidelines: NHS TA91 [119] Primary studies: [155, 156, 158, [164] [165] [166] [167] [168] [169] [170] [171] Note: Platinum-resistant recurrence: recurrence within 6 months after completing primary therapy Quality indicator 10: Combination therapy for platinum-sensitive recurrence Z: Number of pts. receiving platinum-based combination therapy N: All pts. with platinum-sensitive recurrence of ovarian cancer receiving chemotherapy for recurrence outside clinical trials 9.5 Patients with platinum-sensitive recurrence of ovarian cancer must receive platinum-based combination therapy, if chemotherapy is indicated. The following combinations of cytostatic drugs can be considered: " carboplatin/gemcitabine/bevacizumab* " carboplatin/pegylated liposomal doxorubicin " carboplatin/paclitaxel " carboplatin/gemcitabine a) Quality target Platinum-based combination therapy to be administered as often as possible to treat patients with platinum-sensitive recurrence receiving chemotherapy for recurrence outside clinical trials b) Evidence base CC Guidelines: [1] Primary studies: [155, 157, 171, 237, 238] Note: Platinum-based combination therapy: carboplatin/gemcitabine/bevacizumab*, carboplatin/pegylated liposomal doxorubicin, carboplatin/paclitaxel, carboplatin/gemcitabine Quality indicator 11: Counselling by social services Z: Number of pts who received counselling by social services N: All pts. with a primary diagnosis of ovarian cancer being treated in the facility 10.1. Patients with ovarian cancer must receive information about the available rehabilitation and support from social services and must be offered suitable support based on their individual need.
Patients with a primary diagnosis of ovarian cancer to receive counselling from social services as often as possible b) Evidence base CC Guidelines: [1] Primary studies: [14, 178, 179] Quality indicator 12: No adjuvant therapy for BOT Z: Number of pts. with adjuvant therapy N: All pts. with a primary diagnosis of BOT 11.6. Patients with borderline tumours must not receive adjuvant therapy.
No adjuvant therapy to be given to patients with BOT b) Evidence base LoE 2+, A Guidelines: [2] Primary studies: [192] * for patients with primary recurrence who did not previously receive VEGF-targeted therapy 
